Statins 74 items
Statins raise Lp(a) modestly; risk on statins persists.
Studies
- OCEAN(a)-DOSE: olpasiran lowers Lp(a) by more than 95 percent in patients with ASCVD (O'Donoghue et al., NEJM 2022)
- Baseline and on-statin Lp(a) predict events in statin trials: patient-level meta-analysis (Willeit et al., Lancet 2018)
- How much Lp(a) lowering equals 1 mmol/L of LDL-C? The Mendelian randomisation answer (Burgess et al., JAMA Cardiol 2018)
- Lp(a) as a cardiovascular risk factor: the first EAS consensus panel (Nordestgaard et al., EHJ 2010)
- Lp(a) risk persists at the lowest achieved LDL-C: participant-level meta-analysis of six statin trials (Bhatia et al., Circulation 2025)
- Alirocumab-induced Lp(a) lowering independently predicts fewer MACE after ACS: ODYSSEY OUTCOMES (Bittner et al., JACC 2020)
- Safety of low Lp(a): no excess of bleeding, malignancy, neurocognitive events or AF, but more diabetes: FOURIER (Gencer et al., EHJ 2026)
- What existing lipid-lowering drugs do to Lp(a): meta-analysis of 147 RCTs (Xie et al., Atherosclerosis 2025)
- Statin therapy increases Lp(a) levels: subject-level meta-analysis of six trials (Tsimikas et al., EHJ 2020)
- Arterial wall inflammation persists in high-Lp(a) patients despite 60 percent LDL-C lowering with evolocumab (Stiekema et al., EHJ 2019)
- Obicetrapib lowers Lp(a) by 37 percent (15 nmol/L) in high-risk patients: pooled analysis (Nicholls et al., EHJ 2026)
- Oxidised phospholipids on apoB predict MACE after ACS and alirocumab abolishes the relation: ODYSSEY OUTCOMES (Tsimikas et al., Circulation 2025)
- Lp(a) and its significance in cardiovascular disease: a review (Duarte Lau and Giugliano, JAMA Cardiol 2022)
- Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
- Lp(a) above 46.8 nmol/L, below current guideline thresholds, still raises MACE risk 20% in statin-treated patients, UK Biobank cohort of 17,376 (Eur J Prev Cardiol 2026)
- Higher Lp(a) linearly predicts faster aortic valve stenosis progression, especially in younger patients, an ASTRONOMER trial secondary analysis of 220 patients (JAMA Cardiol 2018)
- Evacetrapib cuts Lp(a) by up to 40% alone and small LDL particles by up to 95%, a randomised trial of 393 patients (J Clin Lipidol 2016)
- Elevated Lp(a) and oxidized phospholipids predict faster aortic stenosis progression and need for valve replacement, an ASTRONOMER substudy of 220 patients (J Am Coll Cardiol 2015)
- Statins do not lower Lp(a), yet Lp(a) still predicts residual cardiovascular risk after statin therapy, a JUPITER trial analysis of 9612 participants (Circulation 2014)
- Lp(a) above 73 mg/dL predicts future heart attacks in patients with stable coronary disease, the LIPID trial substudy of 7863 patients (Arterioscler Thromb Vasc Biol 2013)
- Niacin lowers Lp(a) by 21% but does not reduce cardiovascular events, the AIM-HIGH trial analysis of apolipoproteins and Lp(a) (J Am Coll Cardiol 2013)
- Lp(a) predicts coronary revascularization need only when LDL cholesterol is above 70 mg/dL, a study of 2769 angiography patients (J Lipid Res 2010)
- Lp(a) predicts cardiovascular events but not cognitive decline in the elderly, the PROSPER study of 5732 people (Atherosclerosis 2005)
- Triple lipid-lowering therapy after ACS cuts LDL-C 59% but raises Lp(a) 91%, Indian cohort of 345 (J Clin Lipidol 2026)
- Elevated Lp(a) predicts higher baseline coronary plaque burden and faster low-attenuation plaque growth on serial CT angiography (Front Cardiovasc Med 2026)
- Rising Lp(a) independently predicts coronary plaque progression on serial IVUS despite aggressive statin therapy, in 79 CAD patients (Sci Rep 2025)
- Nearly one in three Argentines has elevated Lp(a), and it predicts MACE most strongly in statin-naive patients, GAELp(a) registry of 3,000 finds (Atherosclerosis 2025)
- Meta-analysis of 43 randomised trials confirms statins do not meaningfully change Lp(a) levels (Rev Cardiovasc Med 2025)
- Statin therapy does not meaningfully change Lp(a), a Dutch meta-analysis of 39 trials and 24,448 participants (Eur J Prev Cardiol 2022)
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
- Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial
- Higher Lp(a) predicts cardiovascular events in 393 Chinese patients with familial hypercholesterolaemia despite statin treatment (Atherosclerosis 2019)
- Starting statins raises Lp(a) only in patients with the low molecular weight apo(a) phenotype, a study of 81 patients (Atherosclerosis 2019)
- Evolocumab lowers Lp(a) by cutting production alone, but by speeding clearance when combined with atorvastatin, a kinetic trial of 63 men (Eur Heart J 2018)
- Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial
- Diabetes lowers Lp(a) but raises PCSK9, and CETP inhibition with torcetrapib cuts Lp(a) by 11.1%, a clinical trial analysis (J Clin Lipidol 2018)
- CETP inhibitor anacetrapib lowers Lp(a) by cutting its production 41%, a kinetic trial of 39 patients (Arterioscler Thromb Vasc Biol 2017)
- Lp(a) does not predict coronary plaque progression during intensive statin therapy, a SATURN substudy of 915 patients (Atherosclerosis 2017)
- Niacin lowers oxidized phospholipids and Lp(a), but statins raise both by over 20%, a study of 591 patients plus a review of 12 trials and 3896 patients (J Clin Lipidol 2016)
- Atorvastatin lowers Lp(a) more than simvastatin, but neither affects apo(a) fragments, a double-blind trial of 391 patients (Atherosclerosis 2002)
- Elevated Lp(a) does not predict restenosis or cardiac events after coronary angioplasty, a FLARE trial analysis of 823 patients (Atherosclerosis 2001)
- LDL-C targets are met in only a fifth of very-high-Lp(a) patients despite statins, Spanish lipid-unit study of 265 (Clin Investig Arterioscler 2026)
- Lp(a) tracks with coronary inflammation in men with HIV and undetectable viral load, and statins do not blunt the link, MACS analysis finds (Eur Heart J Imaging Methods Pract 2026)
- Statins raise Lp(a) while PCSK9 and CETP inhibitors lower it, review of current and emerging therapies (Eur Cardiol 2026)
- Statins and ezetimibe raise oxidized phospholipids on Lp(a) even as PCSK9 inhibitors leave them unchanged, 70-patient study finds (Atheroscler Plus 2025)
- Aggressive lipid-lowering achieved similar LDL-C targets regardless of Lp(a) level in 263 peripheral artery disease patients, with no excess amputation or death at high Lp(a) (Lipids Health Dis 2025)
- Once LDL-C is controlled below 70 mg/dL after PCI, elevated Lp(a) no longer predicts MACE or death, 878-patient Mayo Clinic study finds (Coron Artery Dis 2025)
- Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
- 20-25% of people worldwide have Lp(a) 50 mg/dL or above, and existing drugs barely touch it while three new agents in development could change that, a review (Pharmacotherapy 2023)
- Beyond statins and PCSK9 inhibitors, several non-lipid drug classes also alter Lp(a) levels, a review through January 2023 (Pharmaceuticals 2023)
- Statins raise Lp(a) while PCSK9 inhibitors and RNA therapies lower it, a 57-year literature review of pharmacological effects on Lp(a) (Endocr Pract 2023)
- No statin type or dose meaningfully lowers Lp(a), a network meta-analysis of 23,605 patients across 20 trials (Pharmacol Res 2021)
- An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
- Ezetimibe does not lower Lp(a), a meta-analysis of 10 randomised trials and 5188 patients (Sci Rep 2018)
- Fibrates lower Lp(a) more than statins, and adding fibrates boosts statins effect, a meta-analysis of 16 head-to-head trials and 1388 patients (BMC Med 2017)
- Adding L-carnitine to simvastatin modestly lowers Lp(a) by 19%, a randomised trial of two 29-patient groups (Lipids 2017)
- One Lp(a) test can reclassify up to 40% of intermediate-risk patients, a review of Lp(a) re-emergence in clinical practice (Prog Cardiovasc Dis 2016)
- Adding L-carnitine to simvastatin lowers Lp(a) in type 2 diabetes, while simvastatin alone raises it, a randomised trial of 52 patients (Atherosclerosis 2006)
- Diet and exercise raise Lp(a) by 20% in obese African-Americans, while statins push it up 30%, a study of 343 patients (Atherosclerosis 2004)
- Lipoprotein(a) in familial hypercholesterolemia
- Adding Lp(a) to SCORE2 reclassified most moderate-risk patients to high risk and made 61% eligible for statins, 140-subject study finds (Biomedicines 2025)
- PCSK9 gain-of-function gene variants show no measurable effect on lipids or arterial wall properties in statin-treated post-MI patients with severely elevated Lp(a) (Sci Rep 2025)
- Lp(a) of 97.5 mg/L predicts coronary heart disease in type 2 diabetes, and six months of rosuvastatin does not budge it (Rev Assoc Med Bras 2025)
- Review traces why statins raise Lp(a) while PCSK9 inhibitors lower it, and what that means for residual cardiovascular risk (Clin Chim Acta 2025)
- Rosuvastatin, with or without fenofibrate, raises Lp(a) despite lowering LDL cholesterol in a post-hoc analysis of 47 patients with mixed hyperlipidaemia (Arch Med Sci Atheroscler Dis 2024)
- Statin therapy masks the inverse relationship between kidney function and Lp(a) in 149 Japanese patients with type 2 diabetes (J Atheroscler Thromb 2024)
- Despite decades of study, how the liver assembles and clears Lp(a) remains only partly understood, a comprehensive metabolism review (Atherosclerosis 2022)
- Statins, fibrates and bile acid sequestrants fail to lower Lp(a), leaving newer ASOs, CETP and PCSK9 inhibitors as the most effective options, a review (Am J Cardiovasc Drugs 2021)
- Lp(a) is genetically fixed and diet-resistant, a review of its biology and response to statins, apheresis, PCSK9 and CETP inhibitors and antisense drugs (J Mol Cell Cardiol 2019)
- Whether lowering Lp(a) on top of statins reduces cardiovascular risk remains unproven, a review of PCSK9 inhibitors and antisense drugs (Curr Atheroscler Rep 2019)
- How PCSK9 antibodies lower Lp(a) remains unexplained, unlike statins which raise LDL receptor activity without lowering Lp(a), a review since 2012 (Clin Sci (Lond) 2017)
- Lipid-lowering therapy reduces oxidised-apoB immune complexes but not other oxidative markers in patients with Lp(a) 75 nmol/L or more (Clin Res Cardiol 2026)
- Diagnostic and Severity Assessment of Coronary Artery Disease Using ApoB/ApoA-I Ratio: Insights from a Statin-Treated Eastern European Cohort